Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.
Albert Chiou, MD, MBA
Advertisement
Albert Chiou, MD, MBA, is a board-certified dermatologist and clinical associate professor of dermatology at the Stanford University School of Medicine in California.
Articles by Albert Chiou, MD, MBA
Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.
Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Study Suggests Non-Ablative Fractional Laser Reverses Epigenetic Signatures of Skin Aging
2
The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines
3
Social Media Mythbusters: PDRN Serums
4
Bempikibart Shows Positive Phase 2a Results in Alopecia Areata
5